ACE-083
Localised myostatin inhibitor
ACE-083 (Localised myostatin inhibitor) is a gh & growth research compound. A follistatin-based ligand trap injected directly into a specific muscle. It sequesters myostatin and related TGF-beta ligands locally, so hypertrophy is confined to the injected muscle rather than being systemic.
ACE-083 quick facts
| Reported research dose | 150–200mg per muscle (trial doses) |
| Route | Intramuscular (local) |
| Frequency | Every 3 weeks in trials |
| Half-life | Local depot effect; dosed every 3 weeks in trials |
| Forms | Injectable |
| Evidence level | Phase 2 trials — muscle volume increased, but strength and function did not follow |
The trial result is the honest headline and it's a disappointment: in facioscapulohumeral muscular dystrophy and Charcot-Marie-Tooth, ACE-083 **increased muscle volume but produced no improvement in function or strength**, and development was discontinued. Bigger muscle that doesn't do more. Anyone selling this as localised growth should be quoting that finding.
How ACE-083 works
A follistatin-based ligand trap injected directly into a specific muscle. It sequesters myostatin and related TGF-beta ligands locally, so hypertrophy is confined to the injected muscle rather than being systemic.
Proposed benefits
Researched for lean-mass support, recovery, sleep depth, connective-tissue repair and improved body composition via the GH/IGF-1 axis.
✅ Clinically validated
- A real pharmaceutical programme with a real result. Acceleron ran phase 2 trials of ACE-083 in facioscapulohumeral muscular dystrophy and Charcot-Marie-Tooth disease. It reliably increased muscle volume in the injected muscle — that part worked — but did not produce corresponding improvements in strength or function, and development was discontinued.
- That dissociation is the finding worth carrying: bigger muscle and stronger muscle are not the same endpoint, and this is one of the cleanest demonstrations of it in the literature.
📊 Correlative data
- Essentially no community use, and that absence is itself informative — it was never widely available after Acceleron shut the programme, so unlike most compounds here there is no anecdotal record to weigh against the trial. What you see is what there is: a well-run phase 2 that produced measurable hypertrophy and no functional gain.
🧪 Theoretical / extrapolated
- A locally-acting myostatin/activin ligand trap, designed for intramuscular injection so the effect stays where it is put rather than acting systemically.
- The local design is what made it interesting and what the trial result complicates: hypertrophy without functional gain suggests the added tissue was not contributing normally, which is a caution for every myostatin-targeting approach.
These tiers tell you how much human evidence exists — not how well something works. This is the research space, and most of what’s in here is new rather than disproven. Something sitting at “theoretical” usually means nobody has funded the trial, not that the trial was run and failed.
The trap runs the other way too: something can be clinically validated and still do very little for you specifically. A statistically significant result in a study population is not a promise about your body.
- ✅ Clinically validated — human randomised trials or meta-analyses support it. The strongest footing available.
- 📊 Correlative — observational or epidemiological data. Suggestive, and genuinely useful for direction, but it cannot establish cause.
- 🧪 Theoretical / mechanistic — the mechanism is understood and often demonstrated in cells or animals, and the human trial doesn’t exist yet. Unproven is not the same as ineffective. Plenty of what’s standard practice today sat here five years ago.
✗ is a safety flag, not a grade. Where you see it, the concern is harm — not a disappointing trial. A compound tested for one purpose and found not to help there can still be worth studying somewhere else, so a negative result never gets rendered as a cross. It sits alongside the tier, because something can be both well-studied and genuinely risky.
My job is to tell you which one you’re looking at, and let you make the call. Grading something low isn’t me dismissing it — it’s me refusing to oversell it. This is the research space, and being able to reason forward from a mechanism matters as much as waiting for the trial.
ACE-083 — safety, predicted from mechanism
Much of this compound class has never been through a human safety trial. Rather than say nothing — or print a generic warning — this is what its known mechanism predicts could go wrong, and what you can do about it. Predictions are labelled as predictions.
What the mechanism predicts
Derived from what this molecule does, not from a trial.
- These inhibit myostatin or activin signalling — the brake on muscle growth. Removing a brake the body installed deliberately is the whole premise, and the predicted problems follow from that.
- Myostatin and activin are not muscle-only signals. The same TGF-β family regulates tendon and connective tissue, and the concern that follows is muscle gaining force capacity faster than tendon adapts — predicting tendon and joint injury rather than muscle injury.
- Activin signalling also has roles in reproduction and inflammation, so systemic inhibition has predicted consequences well beyond the muscle the user is aiming at.
What has actually been reported
- Trials of myostatin-pathway drugs have repeatedly shown the dissociation that matters: muscle mass increases without a proportional increase in strength or function. That result recurs across programmes and is the main reason several were discontinued.
- Bimagrumab produced muscle gain and fat loss in trials alongside diarrhoea and muscle spasms.
- YK-11 has no human trial data at all. It is frequently described as a myostatin inhibitor on the strength of a single cell-culture study.
How to reduce the risk
Each of these follows from the same mechanism as the prediction.
- If tendon lags muscle, the answer is loading tendon deliberately — slow heavy resistance work — and not adding load as fast as the new muscle allows.
- Treat rapid strength gain as a reason to be more conservative with progression, not less.
What it does to your bloodwork
A fact about the assay, not a guess about the drug.
- Liver function, especially for the oral compounds in this group. Creatine kinase if you are getting unusual soreness or spasm.
Don't run this if
- You have a history of tendon injury, or you are progressing loading aggressively already.
The honest unknown
- Almost everything. No compound in this group has established long-term human safety, and the consistent trial finding is that mass gained this way has not translated into function.
Not medical advice. If you take prescription medication or have a diagnosed condition, check this with a pharmacist or doctor.
Where to get ACE-083
Buy ACE-083 at Disguised Alpha →ACE-083 — interference & stacking
Predicted from mechanism, not from an interaction study. There are no trials of these combinations — what follows is what the biology implies, so treat it as a reason to watch something, not as a finding.
What ACE-083 moves on your bloodwork
These are the markers this compound is expected to move, and which direction. Knowing that in advance is mostly about NOT panicking: some of these moving is the compound working.
- IGF-1 (Insulin-like Growth Factor 1) — ↑ expected to rise
This is the point. IGF-1 rising is the compound doing its job — it is the stable downstream readout of a GH pulse.
What to do: Test it before you start and again at 6–8 weeks. It is the only number that tells you whether the product was real and the dose was enough. - Growth Hormone, Serum — ✕ unreliable here
A random GH level is close to meaningless here. GH is secreted in pulses during deep sleep and sits undetectable between them, so a daytime draw catches a trough almost every time — including when the compound is working perfectly.
What to do: Do not use GH to judge a secretagogue. Read IGF-1 instead. - Fasting Insulin — ↑ expected to rise
GH is a counter-regulatory hormone: it opposes insulin. Fasting insulin and glucose drifting up is the predicted trade-off, not a surprise.
What to do: Check fasting insulin and HbA1c at baseline and again at 8–12 weeks. This is the marker that decides whether you keep running it. - HbA1c (Hemoglobin A1c) — ↑ expected to rise
Same mechanism, longer window — a slow drift rather than a jump.
What to do: Pair it with fasting insulin; either alone can mislead. - Free T4 (Thyroxine) — ↓ expected to fall
GH accelerates the peripheral conversion of T4 to T3, so free T4 can fall while free T3 holds or rises. Read alone it looks like new hypothyroidism, and it usually isn't.
What to do: Run a full thyroid panel rather than TSH alone before concluding anything.
- Which compounds push the same lever, and why the dose adds up faster than people count
- What blunts it — the stacks that waste your money
- What compounds the risk, so a side effect arrives sooner than any one of them suggests
- Coach Cam's read on running it alongside the rest of your protocol
Get the complete breakdown for ACE-083 — inside the Academy alongside the full interactive Vault.
Unlock in the Academy — $10/mo →Everything above follows from one fact: these raise GH and therefore IGF-1. Nothing here needs a trial of the specific molecule.
- How to work up to it, and when not to
- When to take it, and why that window
- Cycle length
- Time off between cycles
- Fasted or fed, and when in the day
- Coach Cam's personal notes
Get the complete breakdown for ACE-083 — inside the Academy alongside the full interactive Vault.
Unlock in the Academy — $10/mo →Bloodwork to run alongside ACE-083
Run these before you start, and again after 8–12 weeks. A baseline you didn’t take is one you can never go back for.
| Marker | What it’s watching for |
|---|---|
| IGF-1 (Insulin-like Growth Factor 1) | The number that actually tracks your GH exposure — dose by this, not by feel |
| Fasting Insulin | GH raises insulin resistance; this moves before glucose does |
| HbA1c (Hemoglobin A1c) | The slower confirmation that the insulin change is real |
| Comprehensive Metabolic Panel (CMP) | Fasting glucose, and liver and kidney at baseline |
The Running GH Peptides or MK-677 panel covers these in one order — 9 markers, $132.30 with the discount applied.
Check results you already have → · All 102 markers A–Z
ACE-083 — frequently asked questions
What is ACE-083?
ACE-083 (Localised myostatin inhibitor) is a gh & growth research compound. A follistatin-based ligand trap injected directly into a specific muscle. It sequesters myostatin and related TGF-beta ligands locally, so hypertrophy is confined to the injected muscle rather than being systemic.
Is the full ACE-083 protocol on this page?
The reported research dose is on this page, along with how ACE-083 works and the evidence behind it. The protocol — how to work up to it, frequency, cycle length, time off, what not to stack it with and Coach Cam's notes — is inside the Academy.
What is the half-life of ACE-083?
ACE-083 has an approximate half-life of Local depot effect; dosed every 3 weeks in trials, which is part of what determines how often it's dosed.
What's the evidence behind ACE-083?
Current evidence level: Phase 2 trials — muscle volume increased, but strength and function did not follow. ACE-083 is offered for research purposes only and is not an approved medicine.
Want Coach Cam's exact ACE-083 protocol?
Dosing schedules, stacking, cycle timing and my personal notes live inside the Academy — plus the full interactive Vault of 237 compounds & 350 supplements.
Join the Academy — $10/mo →What ACE-083 is used for
ACE-083 appears under 2 goals in the Vault’s goal router, grouped by the mechanism it works through rather than by how much trial evidence exists. Each link opens that pathway in full, with the alternatives beside it and the bloodwork that tests it.